Exosome-transmitted miR-3124-5p promotes cholangiocarcinoma development via targeting GDF11

Gao, Huijie; He, Zhiwei; Gao, Chao; Liu, Naiqing; Zhang, Zhaoyang; Niu, Weibo; Ni, Jun; Peng, Cheng

doi:10.3389/fonc.2022.936507

Cited by 7 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes of patients with cholangiocarcinoma exhibited elevated miR‐3124‐5p levels which contribute to cancer cell proliferation migration and angiogenesis through downregulation of GDF11 expression. Consequently, downregulation of GDF11 may be responsible for enhancing cholangiocarcinoma aggression 99 …”

Section: Gdf11 In Liver‐associated Diseasesmentioning

confidence: 99%

“…Consequently, downregulation of GDF11 may be responsible for enhancing cholangiocarcinoma aggression. 99 Table 2 summarizes the effects of GDF11 on cancers of the liver.…”

Section: Gdf11 and Liver Cancermentioning

confidence: 99%

“…Consequently, downregulation of GDF11 may be responsible for enhancing cholangiocarcinoma aggression. 99 …”

Section: Gdf11 In Liver‐associated Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

GDF11: An emerging therapeutic target for liver diseases and fibrosis

Habibi,

Falamarzi,

Ebrahimi

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11 (BMP11), has been identified as a key player in various biological processes, including embryonic development, aging, metabolic disorders and cancers. GDF11 has also emerged as a critical component in liver development, injury and fibrosis. However, the effects of GDF11 on liver physiology and pathology have been a subject of debate among researchers due to conflicting reported outcomes. While some studies suggest that GDF11 has anti‐aging properties, others have documented its senescence‐inducing effects. Similarly, while GDF11 has been implicated in exacerbating liver injury, it has also been shown to have the potential to reduce liver fibrosis. In this narrative review, we present a comprehensive report of recent evidence elucidating the diverse roles of GDF11 in liver development, hepatic injury, regeneration and associated diseases such as non‐alcoholic fatty liver disease (NAFLD), non‐alcoholic steatohepatitis (NASH), liver fibrosis and hepatocellular carcinoma. We also explore the therapeutic potential of GDF11 in managing various liver pathologies.

show abstract

Section: Gdf11 In Liver‐associated Diseasesmentioning

confidence: 99%

“…Consequently, downregulation of GDF11 may be responsible for enhancing cholangiocarcinoma aggression. 99 Table 2 summarizes the effects of GDF11 on cancers of the liver.…”

Section: Gdf11 and Liver Cancermentioning

confidence: 99%

See 1 more Smart Citation

GDF11: An emerging therapeutic target for liver diseases and fibrosis

Habibi,

Falamarzi,

Ebrahimi

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The upregulation of GDF11 can promote the occurrence and development of related tumors. In liver cancer (28, 29), pancreatic cancer ( 8 ), es op hageal cancer (3 0), and cholangiocarcinoma (31), the expression of GDF11 is downregulated. However, when GDF11 is overexpressed, the progression of the above tumors is inhibited.…”

Section: Cancer Cellsmentioning

confidence: 99%

The regulatory effect of growth differentiation factor 11 on different cells

Shao,

Liu,

Wen

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Growth differentiation factor 11 (GDF11) is one of the important factors in the pathophysiological process of animals. It is widely expressed in many tissues and organs of animals, showing its wide biological activity and potential application value. Previous research has demonstrated that GDF11 has a therapeutic effect on various diseases, such as anti-myocardial aging and anti-tumor. This has not only sparked intense interest and enthusiasm among academics but also spurred some for-profit businesses to attempt to develop GDF11 as a medication for regenerative medicine or anti-aging application. Currently, Sotatercept, a GDF11 antibody drug, is in the marketing application stage, and HS-235 and rGDF11 are in the preclinical research stage. Therefore, we believe that figuring out which cells GDF11 acts on and its current problems should be an important issue in the scientific and commercial communities. Only through extensive, comprehensive research and discussion can we better understand the role and potential of GDF11, while avoiding unnecessary risks and misinformation. In this review, we aimed to summarize the role of GDF11 in different cells and its current controversies and challenges, providing an important reference for us to deeply understand the function of GDF11 and formulate more effective treatment strategies in the future.

show abstract

“…GDF11 acts as a tumor suppressor in triple-negative breast cancer by preserving epithelial cell-cell adhesion and inhibiting cell invasion (8). Furthermore, colorectal cancer-associated human intestinal lymphatic endothelial cells have been reported to promote tumor cell proliferation via the soluble matrisome component GDF11 (9). Exosome-transmitted microRNA-3124-5p promotes cholangiocarcinoma development by targeting GDF11 (10).…”

Section: Introductionmentioning

confidence: 99%

GDF11 inhibits the malignant progression of hepatocellular carcinoma via regulation of the mTORC1‑autophagy axis

Wu,

Fan,

Liu

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignant tumor, which is associated with a poor prognosis and high mortality rate. It is well known that growth differentiation factor 11 (GDF11) acts as a tumor suppressor in various types of cancer, including HCC. The present study aimed to determine the tumor-suppressive properties of GDF11 in HCC and to assess the intrinsic mechanisms. In the present study, the human hepatoma cell line Huh-7 was transfected with the GDF11 overexpression plasmid (Oe-GDF11) for gain-of-function experiments to investigate the effects of GDF11 on the biological behaviors of HCC cells, including proliferation, colony formation, apoptosis, cell cycle arrest, migration, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. The proliferation, colony formation, apoptosis, cell cycle, migration, invasion and angiogenesis of HCC cells were assessed by CCK-8, EdU staining, colony formation, flow cytometry, wound healing, Transwell and tube formation assays, respectively. Apoptosis-, cell cycle-, EMT-related key factors were also determined by western blot assay. Furthermore, Oe-GDF11-transfected Huh-7 cells were treated with the mammalian target of rapamycin (mTOR) activator MHY1485 for rescue experiments to explore whether GDF11 could exert antitumor effects against HCC via mediating the mTOR complex 1 (mTORC1)-autophagy axis. In the present study, GDF11 was verified to be lowly expressed in HCC cells. Overexpression of GDF11 inhibited the proliferation, colony formation, migration, invasion, EMT and angiogenesis of HCC cells, and facilitated the apoptosis and cell cycle arrest of HCC cells. Additionally, it was verified that overexpression of GDF11 inactivated the mTORC1 signaling pathway to enhance autophagy in HCC cells. Treatment with the mTOR activator MHY1485 partially reversed the tumor-suppressive effects of GDF11 overexpression on HCC. In conclusion, GDF11 may exert tumor-suppressive properties in HCC cells through inactivating the mTORC1 signaling pathway to strengthen autophagy.

show abstract

Exosome-transmitted miR-3124-5p promotes cholangiocarcinoma development via targeting GDF11

Cited by 7 publications

References 41 publications

GDF11: An emerging therapeutic target for liver diseases and fibrosis

GDF11: An emerging therapeutic target for liver diseases and fibrosis

The regulatory effect of growth differentiation factor 11 on different cells

GDF11 inhibits the malignant progression of hepatocellular carcinoma via regulation of the mTORC1‑autophagy axis

Contact Info

Product

Resources

About